See more : Abacus Life, Inc. (ABL) Income Statement Analysis – Financial Results
Complete financial analysis of Arrowhead Pharmaceuticals, Inc. (ARWR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Arrowhead Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kimbell Tiger Acquisition Corporation (TGR-WT) Income Statement Analysis – Financial Results
- Oakridge International Limited (OAK.AX) Income Statement Analysis – Financial Results
- Lenzing Aktiengesellschaft (LEN.DE) Income Statement Analysis – Financial Results
- Pure Energy Minerals Limited (PEMIF) Income Statement Analysis – Financial Results
- Hangcha Group Co., Ltd (603298.SS) Income Statement Analysis – Financial Results
Arrowhead Pharmaceuticals, Inc. (ARWR)
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 3.55M | 240.74M | 243.23M | 138.29M | 87.99M | 168.80M | 16.14M | 31.41M | 158.33K | 382.00K | 175.00K | 290.27K | 146.88K | 296.14K | 620.10K | 3.77M | 1.30M | 1.21M | 595.46K | 590.68K | 196.31K | 0.00 | 2.27K | 9.31K | 24.88K | 37.00K | 60.38K | 76.59K |
Cost of Revenue | 0.00 | 0.00 | 10.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 724.09K | 0.00 | 0.00 | 0.00 | 0.00 | 87.00 | 6.30K | 2.09K | 2.85K | 33.79K | 36.97K |
Gross Profit | 3.55M | 240.74M | 232.81M | 138.29M | 87.99M | 168.80M | 16.14M | 31.41M | 158.33K | 382.00K | 175.00K | 290.27K | 146.88K | 296.14K | 620.10K | 3.77M | 1.30M | 483.93K | 595.46K | 590.68K | 196.31K | 0.00 | 2.18K | 3.02K | 22.78K | 34.15K | 26.59K | 39.62K |
Gross Profit Ratio | 100.00% | 100.00% | 95.72% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 40.06% | 100.00% | 100.00% | 100.00% | 0.00% | 96.16% | 32.38% | 91.58% | 92.29% | 44.04% | 51.73% |
Research & Development | 505.87M | 353.19M | 297.31M | 206.34M | 128.87M | 81.05M | 52.97M | 31.69M | 41.45M | 57.41M | 23.14M | 8.71M | 5.39M | 3.28M | 1.11M | 8.97M | 12.14M | 20.93M | 8.58M | 3.79M | 793.35K | 3.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 98.76M | 90.93M | 124.43M | 80.98M | 52.28M | 26.56M | 19.11M | 32.02M | 41.00M | 34.72M | 24.42M | 11.69M | 14.10M | 5.23M | 8.00M | 14.14M | 6.85B | 4.39B | 5.03B | 2.68M | 914.85K | 0.00 | 0.00 | 0.00 | 0.00 | 56.18K | 12.44K | 11.28K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -6.82B | -4.37B | -5.02B | 3.32M | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 34.18K | 38.14K | 78.48K |
SG&A | 98.76M | 90.93M | 124.43M | 80.98M | 52.28M | 26.56M | 19.11M | 32.02M | 41.00M | 34.72M | 24.42M | 11.69M | 14.10M | 5.23M | 8.00M | 14.14M | 23.75M | 17.09M | 12.26M | 5.99M | 2.17M | 91.06K | 143.80K | 109.28K | 132.02K | 90.36K | 50.58K | 89.76K |
Other Expenses | 0.00 | 1.62M | 5.80M | 2.07M | -582.52K | 0.00 | 7.49K | 1.31M | 57.35K | 417.87K | 82.09K | -997.98K | 9.41B | 3.03B | 5.13B | 9.87B | 17.31B | 7.65B | 8.22B | 3.32M | 1.26M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 604.63M | 445.74M | 421.74M | 287.32M | 181.15M | 107.60M | 72.08M | 68.40M | 79.85M | 96.36M | 51.28M | 23.57M | 21.24M | 10.13M | 9.42M | 23.50M | 36.31M | 38.43M | 21.84M | 9.95M | 2.97M | 94.44K | 1.42M | 109.28K | 132.02K | 90.36K | 68.89K | 198.24K |
Cost & Expenses | 604.63M | 445.74M | 421.74M | 287.32M | 181.15M | 107.60M | 72.08M | 68.40M | 79.85M | 96.36M | 51.28M | 23.57M | 21.24M | 10.13M | 9.42M | 23.50M | 36.31M | 39.16M | 21.84M | 9.95M | 2.97M | 94.44K | 1.42M | 115.58K | 134.11K | 93.21K | 102.67K | 235.21K |
Interest Income | 22.72M | 15.30M | 5.03M | 6.12M | 9.19M | 6.96M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.67K | 736.34M | 0.00 | 0.00 | 151.05K | 33.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 32.35M | 18.33M | 5.03M | 6.12M | 9.19B | 6.96B | 1.05B | 415.13M | 265.79M | 729.16M | 645.49M | 0.00 | 35.97M | 86.53M | 0.00 | 150.89K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 18.60M | 12.49M | 10.42M | 8.27M | 5.94M | 4.44M | 4.70M | 4.69M | 3.26M | 2.34M | 1.35M | 1.75M | 1.75M | 267.98K | 654.69K | 994.60K | 1.13M | 1.00M | 886.96K | 644.01K | 74.74K | 90.00 | 9.08K | 3.53K | 7.62K | 8.12K | 18.31K | 103.79K |
EBITDA | -561.51M | -175.67M | -162.29M | -132.58M | -87.22M | 65.63M | -51.24M | -29.69M | -78.46M | -89.60M | -47.38M | -20.11M | -19.34M | -8.52M | -6.68M | -18.16M | -33.25M | -35.68M | -19.43M | -8.95M | -2.67M | -94.35K | -1.41M | -102.74K | -101.61K | -48.10K | -15.11K | -54.83K |
EBITDA Ratio | -15,812.81% | -72.97% | -73.39% | -101.79% | -99.12% | 38.88% | -320.08% | -105.69% | -46,787.48% | -25,268.65% | -23,710.47% | -5,114.27% | -12,611.40% | -3,607.83% | -1,585.65% | -499.08% | -2,598.92% | -3,058.36% | -3,303.39% | -1,878.10% | -1,366.25% | 0.00% | -64,419.02% | -1,750.46% | -785.70% | 428.30% | -92.33% | 837.03% |
Operating Income | -601.08M | -205.00M | -178.51M | -149.04M | -93.16M | 61.19M | -55.94M | -37.00M | -81.74M | -95.97M | -53.28M | -24.59M | -21.09M | -9.83M | -8.80M | -19.73M | -35.00M | -37.95M | -21.24M | -9.36M | -2.77M | -94.44K | -1.42M | -106.27K | -109.24K | -56.22K | -42.30K | -158.62K |
Operating Income Ratio | -16,927.06% | -85.16% | -73.39% | -107.77% | -105.87% | 36.25% | -346.52% | -117.79% | -51,627.09% | -25,124.08% | -30,443.59% | -8,471.29% | -14,358.61% | -3,319.48% | -1,419.46% | -522.87% | -2,685.89% | -3,141.43% | -3,567.11% | -1,585.07% | -1,410.50% | 0.00% | -62,498.41% | -1,141.16% | -439.08% | -151.94% | -70.05% | -207.10% |
Total Other Income/Expenses | -11.38M | -1.49M | 5.80M | 8.19M | 8.61M | 6.96M | 1.49M | 2.62M | 22.12K | 4.04M | -5.44M | -7.11M | -1.02M | 1.05M | 1.42M | -1.87M | -2.65M | -8.33M | 169.58K | 2.76M | 272.75K | 0.00 | 1.17M | -79.56K | -28.32K | -312.24K | -140.73K | -695.92K |
Income Before Tax | -612.46M | -206.49M | -172.71M | -140.85M | -84.55M | 68.15M | -54.45M | -34.38M | -81.72M | -91.94M | -58.72M | -31.70M | -22.11M | -8.79M | -7.34M | -19.16M | -35.12M | -37.95M | -21.92M | -6.99M | -2.50M | -94.44K | -246.21K | -185.82K | -137.55K | -368.46K | -10.54K | -854.54K |
Income Before Tax Ratio | -17,247.54% | -85.78% | -71.01% | -101.85% | -96.09% | 40.37% | -337.30% | -109.46% | -51,613.12% | -24,067.67% | -33,554.35% | -10,922.08% | -15,054.05% | -2,966.52% | -1,183.10% | -507.73% | -2,694.70% | -3,141.40% | -3,681.87% | -1,183.02% | -1,271.56% | 0.00% | -10,865.27% | -1,995.50% | -552.91% | -995.89% | -17.45% | -1,115.73% |
Income Tax Expense | -2.77M | 2.78M | 3.79M | 2.00K | 2.40K | 173.55K | 2.40K | 2.40K | 2.40K | 2.40K | 5.30K | 6.22M | -203.44K | -6.86M | -3.25M | 53.95K | -8.03M | -8.02M | -2.24M | -2.74M | 800.00 | 800.00 | -1.17M | 79.56K | 28.32K | -649.22K | 9.32K | 695.92K |
Net Income | -599.49M | -205.28M | -176.49M | -140.85M | -84.55M | 67.97M | -54.45M | -34.38M | -81.72M | -91.94M | -58.63M | -31.14M | -21.13M | -3.13M | -5.77M | -19.31M | -27.09M | -29.93M | -19.00M | -6.62M | -2.50M | -95.24K | -246.21K | -185.82K | -137.55K | 593.00K | -51.62K | -854.54K |
Net Income Ratio | -16,882.37% | -85.27% | -72.56% | -101.85% | -96.09% | 40.27% | -337.32% | -109.46% | -51,614.64% | -24,068.29% | -33,502.97% | -10,729.22% | -14,383.61% | -1,056.56% | -931.15% | -511.73% | -2,078.65% | -2,477.70% | -3,190.35% | -1,121.55% | -1,271.96% | 0.00% | -10,865.27% | -1,995.50% | -552.91% | 1,602.80% | -85.49% | -1,115.73% |
EPS | -5.00 | -1.91 | -1.67 | -1.36 | -0.84 | 0.72 | -0.65 | -0.47 | -1.34 | -1.60 | -1.25 | -1.30 | -1.90 | -0.44 | -0.90 | -4.27 | -6.91 | -8.35 | -5.95 | -2.61 | -1.88 | -0.25 | -32.47 | -25.97 | -19.48 | 97.40 | -10.16 | -175.33 |
EPS Diluted | -5.00 | -1.92 | -1.67 | -1.36 | -0.84 | 0.69 | -0.65 | -0.47 | -1.34 | -1.60 | -1.25 | -1.30 | -1.90 | -0.44 | -0.90 | -4.27 | -6.91 | -8.35 | -5.95 | -2.61 | -1.88 | -0.25 | -32.47 | -25.97 | -19.48 | 97.40 | -10.16 | -175.33 |
Weighted Avg Shares Out | 119.78M | 107.31M | 105.43M | 103.75M | 100.72M | 93.86M | 83.64M | 73.15M | 60.99M | 57.36M | 46.90M | 23.96M | 11.12M | 7.18M | 6.43M | 4.52M | 3.92M | 3.59M | 3.20M | 2.54M | 1.33M | 373.88K | 7.58K | 7.15K | 7.06K | 6.09K | 5.08K | 4.87K |
Weighted Avg Shares Out (Dil) | 119.78M | 106.75M | 105.43M | 103.75M | 100.72M | 98.61M | 83.64M | 73.90M | 61.05M | 57.36M | 46.93M | 24.00M | 11.13M | 7.18M | 6.43M | 4.52M | 3.92M | 3.59M | 3.20M | 2.54M | 1.33M | 373.88K | 7.58K | 7.15K | 7.06K | 6.09K | 5.08K | 4.87K |
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
The 7 Most Undervalued Russell 2000 Stocks to Buy in April 2024
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
The 3 Most Undervalued Russell 2000 Stocks to Buy in March 2024
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
7 Oversold Russell 2000 Stocks to Add to Your February Buy List
Source: https://incomestatements.info
Category: Stock Reports